Gastroparesis Market Positioned for Accelerated Development through 2034

The Gastroparesis Market was valued at approximately USD 150 Million in 2025 and is projected to grow at a robust CAGR during the forecast period (2025-2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Gastroparesis Market Landscape.

By analyzing historical data, current Gastroparesis Market Dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively. The Gastroparesis Market is increasingly guided by biomarker-driven strategies.

DelveInsight’s report, “Gastroparesis Treatment Market Insights, Epidemiology, and Market Forecast – 2034,” provides a comprehensive analysis of the Gastroparesis Market landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines the Gastroparesis Market Dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the Gastroparesis Market Outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Gastroparesis Market Forecast

Some of the key facts of the Gastroparesis Market Report

• The leading Gastroparesis Companies such as Vanda Pharmaceuticals, Processa Pharmaceuticals, Evoke Pharmaceuticals, Neurogastrx, CinDome Pharma, Renexxion Ireland, Dr. Falk Pharma GmbH, Aclipse Therapeutics, Chong Kun Dang Pharmaceuticals, RaQualia Pharma and others.
• Promising Gastroparesis Therapies such as Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, VLY-686 (Tradipitant), Camicinal, GM-611, GSK962040 (25 mg tablet), TC-6499, and others.
• The Gastroparesis Market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroparesis Pipeline products will significantly revolutionize the Gastroparesis Market Dynamics.

Gastroparesis Overview

Gastroparesis is a chronic medical condition in which the stomach muscles don’t work properly, causing delayed emptying of food from the stomach into the small intestine — even though there’s no physical blockage.

Get a Free sample for the Gastroparesis Market Report @ https://www.delveinsight.com/report-store/gastroparesis-market

Key Trends in Gastroparesis Therapeutics Market

• Market growth driven by rising diabetes prevalence and unmet need

The gastroparesis/drugs market is expanding — several market reports estimate multi-billion dollar value and low-single-digit-to-mid CAGR over the coming decade as diabetic gastroparesis and awareness rise.

• Renewed focus on novel mechanisms (ghrelin agonists, improved prokinetics, NK1/5-HT4 targets)

New molecular approaches (eg. ghrelin receptor agonists such as relamorelin and other prokinetic classes) are the most active area of R&D — with meta-analyses and trials showing improved gastric emptying and symptom benefits in some candidates

• Regulatory uncertainty & mixed clinical readouts

Recent regulatory setbacks (for example the FDA’s Complete Response Letter for tradipitant) show that clinical endpoints and long-term safety requirements remain major barriers to approval.

Gastroparesis Epidemiology

The epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of gastroparesis, etiology-specific cases of gastroparesis, age-specific cases of gastroparesis, gender-specific cases of gastroparesis, total cases of gastroparesis by the severity of delayed gastric emptying, and treated cases of gastroparesis covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

Gastroparesis Epidemiology Segmentation in the 7MM

The Gastroparesis Market Report proffers epidemiological analysis for the study period 2020-2034 in the 7MM, segmented into-

• Total Diagnosed Prevalent Cases of Gastroparesis
• Etiology-Specific Cases of Gastroparesis
• Age-specific Cases of Gastroparesis
• Gender-specific Cases of Gastroparesis
• Total Cases of Gastroparesis by the Severity of Delayed Gastric Emptying
• Treated Cases of Gastroparesis

Download the report to understand which factors are driving Gastroparesis Epidemiology trends @ Gastroparesis Epidemiology Forecast

Recent Development in the Gastroparesis Treatment Landscape

• In October 2025, CinDome Pharma Inc. conducted a clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopathic gastroparesis severity in adult subjects.
• In August 2025, Neurogastrx Inc. conducted a US-based study to evaluate the safety and efficacy of 3 dose levels of NG101 (Metopimazine mesylate) compared with placebo in participants with diabetic or idiopathic gastroparesis.

Gastroparesis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential Gastroparesis drugs recently launched in the Gastroparesis market or expected to be launched during the study period. The analysis covers the Gastroparesis Market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroparesis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroparesis Companies and Therapies

• Vanda Pharmaceuticals: Tradipitant
• Processa Pharmaceuticals: PCS12852
• Theravance Biopharma: Velusetrag dose 1
• Dr. Falk Pharma GmbH: Naronapride
• PTC Therapeutics: CNSA-001

To know more about Gastroparesis Companies working in the treatment market, visit @ Gastroparesis Clinical Trials and Therapeutic Assessment

Gastroparesis Market Drivers

• Rising Prevalence of Diabetes

Diabetes is one of the primary causes of gastroparesis, as it leads to nerve damage affecting stomach motility. With the global diabetic population steadily increasing, the incidence of diabetic gastroparesis is also on the rise. This surge in cases is directly driving the demand for effective gastroparesis treatments and management options.

• Growing Geriatric Population

The aging population is more prone to developing gastrointestinal motility disorders, including gastroparesis. Elderly individuals often have multiple chronic conditions requiring long-term medical care, thereby increasing the need for pharmacological and device-based therapies for gastroparesis management.

• Advancements in Treatment Options

The market is witnessing ongoing innovations in drug development, with new prokinetic agents, antiemetics, and gastric electrical stimulation devices being introduced. These novel therapeutic approaches offer improved efficacy, reduced side effects, and greater convenience, fueling market growth.

• Increasing Awareness and Improved Diagnosis

Healthcare providers and patients are becoming more aware of gastroparesis symptoms, leading to earlier diagnosis and treatment. Technological progress in diagnostic tools, such as non-invasive gastric emptying studies, has improved detection rates and enhanced patient outcomes.

Gastroparesis Market Barriers

• Lack of Effective Treatment Options

Despite the rising prevalence of gastroparesis, there are very few approved therapies that effectively target the underlying cause. Most available treatments only provide symptomatic relief rather than addressing gastric motility dysfunction, which limits patient outcomes and market growth.

• Complex Pathophysiology

Gastroparesis has a multifactorial origin involving neurological, muscular, and hormonal factors, making it difficult to develop targeted therapies. This complexity leads to challenges in drug discovery and clinical trial design.

• High Rate of Misdiagnosis and Underdiagnosis

Symptoms of gastroparesis overlap with other gastrointestinal disorders such as irritable bowel syndrome (IBS) and functional dyspepsia. This diagnostic ambiguity results in delayed or incorrect diagnosis, reducing treatment rates and market penetration.

• Adverse Effects of Current Therapies

Existing drugs like metoclopramide and erythromycin are associated with side effects such as tardive dyskinesia and antibiotic resistance. These safety concerns restrict their long-term use and limit physician and patient adoption.

Scope of the Gastroparesis Market Report

• Coverage- 7MM (The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan)
• Study Period-2020-2034
• Gastroparesis Companies- Vanda Pharmaceuticals, Processa Pharmaceuticals, Evoke Pharmaceuticals, Neurogastrx, CinDome Pharma, Renexxion Ireland, Dr. Falk Pharma GmbH, Aclipse Therapeutics, Chong Kun Dang Pharmaceuticals, RaQualia Pharma and others.
• Gastroparesis Therapies- Tradipitant, PCS12852, Naronapride, CNSA-001, Velusetrag, VLY-686 (Tradipitant), Camicinal, GM-611, GSK962040 (25 mg tablet), TC-6499, and others.
• Gastroparesis Therapeutic Assessment: Gastroparesis Current marketed and Gastroparesis emerging therapies
• Gastroparesis Market Dynamics: Gastroparesis market drivers and Gastroparesis market barriers
• Gastroparesis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Gastroparesis Unmet Needs, KOL’s views, Analyst’s views, Gastroparesis Market Access and Reimbursement

Discover more about therapies set to grab major Gastroparesis Market Share @ Gastroparesis Treatment Market

Table of Contents

1. Key Insights

2. Gastroparesis Report Introduction

3. Gastroparesis Executive Summary

4. Key Events

5. Gastroparesis Epidemiology and Market Forecast Methodology

6. Gastroparesis Market Overview at a Glance

7. Gastroparesis Disease Background and Overview

8. Gastroparesis Treatment

9. Gastroparesis Epidemiology and Patient Population

10. Gastroparesis Patient Journey

11. Gastroparesis Marketed Therapy

12. Gastroparesis Emerging Drugs

13. Gastroparesis: 7MM Market Analysis

14. Gastroparesis Unmet Needs

15. Gastroparesis SWOT Analysis

16. Gastroparesis KOL Views

17. Gastroparesis Market Access and Reimbursement

18. Appendix

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.